Emmanuel Pinard
F. Hoffmann-La Roche Ltd
Pharmaceutical Research Basel
Discovery Chemistry
CH-4070 Basel
Switzerland
Name/email consistency: high
- Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors. Pinard, E., Alberati, D., Borroni, E., Fischer, H., Hainzl, D., Jolidon, S., Moreau, J.L., Narquizian, R., Nettekoven, M., Norcross, R.D., Stalder, H., Thomas, A.W. Bioorg. Med. Chem. Lett. (2008)
- Discovery of N-(2-aryl-cyclohexyl) substituted spiropiperidines as a novel class of GlyT1 inhibitors. Pinard, E., Ceccarelli, S.M., Stalder, H., Alberati, D. Bioorg. Med. Chem. Lett. (2006)
- 4-Aminoquinolines as a novel class of NR1/2B subtype selective NMDA receptor antagonists. Pinard, E., Alanine, A., Bourson, A., Büttelmann, B., Heitz, M., Mutela Ramanjit Gill, V., Trube, G., Wyler, R. Bioorg. Med. Chem. Lett. (2002)
- Discovery of (R)-1-[2-hydroxy-3-(4-hydroxy-phenyl)-propyl]-4-(4-methyl-benzyl)-piperidin-4-ol: a novel NR1/2B subtype selective NMDA receptor antagonist. Pinard, E., Alanine, A., Bourson, A., Büttelmann, B., Gill, R., Heitz, M., Jaeschke, G., Mutel, V., Trube, G., Wyler, R. Bioorg. Med. Chem. Lett. (2001)
